Parexel on Bioeconhttps://en.bioecon.ru/companies/parexel/Recent content in Parexel on BioeconHugoen-USSat, 25 Jul 2026 22:12:11 +0700Named-patient programs & compassionate usehttps://en.bioecon.ru/technology/named-patient-compassionate-use/Sun, 28 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/named-patient-compassionate-use/Regulated pre-approval access to investigational biopharmaceuticals for patients with serious or life-threatening disease and no satisfactory alternative — operated as a managed-access service spanning eligibility, regulatory submission, GMP drug sourcing and pharmacovigilance.CMC regulatory consulting (BLA/MAA)https://en.bioecon.ru/technology/cmc-regulatory-consulting/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/cmc-regulatory-consulting/Specialized strategic advisory services guiding biopharma through the complex Chemistry, Manufacturing, and Controls (CMC) requirements to successfully file Biologics License Applications (BLA) and Marketing Authorisation Applications (MAA).Corporate GMP/GLP/GCP traininghttps://en.bioecon.ru/technology/gmp-glp-gcp-training/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/gmp-glp-gcp-training/Outsourced, regulator-aligned training services that build and maintain GMP, GLP and GCP competency across biopharma workforces, producing inspection-ready training records under 21 CFR Part 11, EU GMP and ICH guidelines.